Lilly reports Q3 2024 financial results highlighted by strong …
INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding divestiture activity in the same period last year," said David A. Ricks, Lilly chair and CEO ...
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry
INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
All News - Eli Lilly and Company
Lilly's latest press releases, stories, news resources and more.
News Release - Eli Lilly and Company
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Lilly.com | Eli Lilly and Company
INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
Aug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
Eli Lilly CEO Dave Ricks discusses obesity, Alzheimer's and AI
16 hours ago · Eli Lilly is the world's most valuable pharma company, with blockbuster drugs for obesity, Alzheimer's and diabetes. CEO Dave Ricks explains how speeding up drugs discovery helps the company succeed.
New Manufacturing Investments | Eli Lilly and Company
Mar 27, 2023 · In Concord, Lilly plans to invest $1 billion to create a new injectable products and devices manufacturing site, along with nearly 600 jobs. Additionally, the company plans to invest $500 million in Limerick to create a new biologics active …
News Release - Eli Lilly and Company
Jul 8, 2024 · INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Eli Lilly and Company - The New York Times
News about Eli Lilly and Company, including commentary and archival articles published in The New York Times.
- Some results have been removed